Status:
UNKNOWN
Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-90 years
Brief Summary
Development of glucocorticoid (GC)-induced adrenal insufficiency is a serious adverse effect of GC treatment. It is today not possible to predict this adverse effect. The project aims at investigating...
Detailed Description
Blood is sampled from patients with rheumatoid arthritis (RA), fulfilling the inclusion criteria and patients are genotyped for the SNPs N363S, BclI, ER22/23EK and 9β and grouped according to haplotyp...
Eligibility Criteria
Inclusion
- Adult patients \> 18 years)
- Caucasian classified with rheumatoid arthritis.
- 1987 ACR-classification criteria.
- Prednisolone min 5mg/day for at least 6 months.
- Presence of either BclI (high GC sensitivity) or 9β (low GC sensitivity)polymorphisms, or wildtype for for all 4 SNPs studied. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not
Exclusion
- Other major organ disease
- Females pregnant
- Females not willing to pause estrogen-containing medications 6 weeks prior to Synacthen® test
- unable to give a written informed content
Key Trial Info
Start Date :
April 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT01411046
Start Date
April 1 2011
End Date
December 1 2017
Last Update
April 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100